Case Report: Step-by-step procedures for total intracorporeal laparoscopic kidney autotransplantation in a patient with distal high-risk upper tract urothelial carcinoma.
kidney autotransplantation
kidney-sparing surgery
total intracorporeal laparoscopic surgery
upper tract urothelial carcinoma
urothelial carcinoma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
01
2023
accepted:
31
03
2023
medline:
12
5
2023
pubmed:
12
5
2023
entrez:
11
5
2023
Statut:
epublish
Résumé
A 47-year-old man presented to the emergency department with right abdominal pain and a new onset of painless haematuria two weeks earlier. Urine cytology test results suggested urothelial carcinoma. Computed tomography urography (CTU) showed a filling defect in the lower right ureter with right hydronephrosis. Lymphadenopathy and any signs of metastatic disease were absent on CTU. Cystoscopy appeared normal. Creatinine level was also normal before surgery. After the treatment options were discussed, the patient chose to undergo 3D total intracorporeal laparoscopic kidney autotransplantation, bladder cuff excision, and segmental resection of the proximal two-thirds of the ureter based on the membrane anatomy concept. After more than one year of follow-up, the patient was in good health and showed no signs of haematuria. Surveillance cystoscopy and CTU examination showed no evidence of disease recurrence. Therefore, it is reasonable to assume that kidney-sparing surgery may be considered for carefully selected patients with high-grade upper tract urothelial carcinoma.
Identifiants
pubmed: 37168366
doi: 10.3389/fonc.2023.1142819
pmc: PMC10164996
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1142819Informations de copyright
Copyright © 2023 Wu, Li, Li, Chen, Xie, Luo, Chen, Ye and Lai.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Urol Int. 2022;106(5):487-494
pubmed: 34844250
World J Urol. 2017 Mar;35(3):379-387
pubmed: 27604375
Eur J Surg Oncol. 2016 Nov;42(11):1625-1635
pubmed: 27612412
Scott Med J. 2023 Feb;68(1):4-13
pubmed: 36576735
J Clin Oncol. 2000 May;18(9):1921-7
pubmed: 10784633
J Clin Oncol. 1999 Sep;17(9):2876-81
pubmed: 10561365
Nat Rev Urol. 2015 Mar;12(3):155-66
pubmed: 25708579
J Clin Oncol. 2021 Aug 1;39(22):2486-2496
pubmed: 33989025
Urology. 2013 May;81(5):972-7
pubmed: 23523292
Eur J Cancer. 2009 Dec;45(18):3291-7
pubmed: 19615885
Surgery. 2022 Nov;172(5):1315-1322
pubmed: 36031446
JAMA Oncol. 2021 Oct 01;7(10):1536-1543
pubmed: 34436521
Eur Urol. 2021 Oct;80(4):507-515
pubmed: 34023164
J Clin Oncol. 2023 Mar 10;41(8):1618-1625
pubmed: 36603175
Eur Urol Open Sci. 2022 May 02;40:104-111
pubmed: 35638087
Sci Rep. 2021 Apr 9;11(1):7828
pubmed: 33837237
World J Urol. 2019 Nov;37(11):2303-2311
pubmed: 31062121
BJU Int. 2019 Jul;124(1):116-123
pubmed: 30712313
J Urol. 2010 Apr;183(4):1324-9
pubmed: 20171666
Urology. 2021 Nov;157:197-200
pubmed: 34274387
J Urol. 2017 Mar;197(3 Pt 1):580-589
pubmed: 27670916
Eur Urol. 2021 Jul;80(1):1-3
pubmed: 32861573
Lancet. 2020 Apr 18;395(10232):1268-1277
pubmed: 32145825
CA Cancer J Clin. 2018 May;68(3):217-231
pubmed: 29485237
J Urol. 2016 Jan;195(1):41-6
pubmed: 26307162
World J Urol. 2020 May;38(5):1165-1175
pubmed: 31321509
Proc Natl Acad Sci U S A. 2020 Aug 4;117(31):18627-18637
pubmed: 32680964
J Clin Oncol. 2000 Sep;18(17):3068-77
pubmed: 11001674
Eur Urol. 2014 Mar;65(3):650-8
pubmed: 24070577
Curr Opin Urol. 2022 Jan 1;32(1):40-47
pubmed: 34608026
Eur Urol. 2021 Jan;79(1):62-79
pubmed: 32593530